Using MRI to predict metastasis in soft tissue sarcoma patients
Prospective Study of Image and Blood-derived Biomarkers to Predict Metastasis in Soft-tissue Sarcomas
PHASE2 · University Health Network, Toronto · NCT05950594
This study is testing if a special type of MRI can help doctors see if soft tissue sarcoma patients have low oxygen levels in their tumors, which could help them choose better treatments right from the start.
Quick facts
| Phase | PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 145 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | University Health Network, Toronto (other) |
| Drugs / interventions | radiation |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT05950594 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of diffusion-weighted magnetic resonance imaging (DWI) combined with intravoxel incoherent motion (IVIM) to assess tumor hypoxia in patients with soft tissue sarcoma (STS). By identifying hypoxia, which is linked to metastasis, the study aims to enable personalized treatment strategies at the time of diagnosis without adding significant burden to patients or clinical workflows. The approach leverages standard MRI techniques that can be performed quickly, potentially improving patient outcomes through better stratification for treatment. The study is conducted at the University Health Network in Toronto.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with grade 2 or 3 soft tissue sarcoma larger than 5 cm.
Not a fit: Patients who have contraindications to MRI scans will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective and personalized treatment plans for patients with soft tissue sarcoma.
How similar studies have performed: Other studies have shown promise in using imaging techniques to assess tumor hypoxia, but this specific approach is novel in the context of soft tissue sarcoma.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Ability to understand and the willingness to sign a written informed consent document * Grade 2 or 3 soft tissue sarcoma greater than 5 cm in largest dimension Exclusion Criteria: * Contraindication to MRI scan as per current institutional guidelines (for patients requiring MRI)
Where this trial is running
Toronto, Ontario
- University Health Network — Toronto, Ontario, Canada (RECRUITING)
Study contacts
- Study coordinator: David Shultz, MD
- Email: david.shultz@rmp.uhn.ca
- Phone: 416-946-4501
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Soft Tissue Sarcoma